Procedure gives patients with A-fib who can't take blood thinners alternative to reduce stroke

May 7, 2012

Patients with atrial fibrillation (A-fib) who cannot take blood thinners now have an alternative to reduce their risk of stroke, which is five times more common in people with the rhythm disorder. The non-surgical procedure works by tying off the left atrial appendage (LAA), the source of most blood clots leading to stroke in patients with A-fib. Northwestern Medicine heart rhythm specialists from the Bluhm Cardiovascular Institute were the first to perform this procedure in Illinois.

"Traditionally, surgery was required to close off the LAA. Now we have the ability to safely and permanently close it using a minimally invasive, non-surgical approach," said Brad Knight, MD, medical director of the Center for at the Bluhm Cardiovascular Institute. "This is an innovative method that has the potential to revolutionize the field of in patients with cardiac rhythm disorders."

The procedure, known as LAA occlusion, is performed using the FDA-approved LARIAT Suture Delivery Device. Doctors access the LAA by inserting a catheter, or thin tube, under the rib cage into the sac around the heart through which the suture to tie off the LAA is delivered. Another catheter is advanced through a blood vessel in the groin up into the heart, and positioned inside the LAA to help guide the suture over the LAA. The eliminates the number one source of heart related stroke, while avoiding the potentially serious side effects associated with blood thinners.

"We are happy to be able to give our patients another option. Non-surgical procedures mean less discomfort and a shorter recovery time," said Albert Lin, MD, associate medical director of at the Bluhm Cardiovascular Institute. "Drug therapies have historically been the first line of defense for patients with A-fib, but they are not tolerated by all patients and can pose serious side effects for some. Now, we have the ability to safely and permanently close the LAA without the need for major surgery and potentially protect against the risk of stroke."

A-fib is a condition where a rapid and irregular heart beat can cause serious complications, including stroke, heart failure and early death. Some people with A-fib have no symptoms and are unaware of their condition until it's discovered during a physical examination. Those who do have A-fib symptoms may experience palpitations or sensations of a racing, irregular heartbeat, shortness of breath, chest pain or lightheadedness. A-fib related deaths have increased over the past two decades and now account for one-quarter of all strokes in the elderly.

"There has recently been a renaissance in the treatment of atrial fibrillation. This latest technological advance represents yet another novel approach to treat ," said Clyde Yancy, MD, chief of the Division of Cardiology and associate director of the Bluhm Cardiovascular Institute.

"This is a great option for patients with A-fib who are at high risk for but cannot safely take ," said Knight. "The procedure is non-invasive and the recovery time is short, so are able to return to their daily activities quickly."

Explore further: Study suggests atrial fibrillation should be surgically treated when performing cardiac surgery

Related Stories

Study suggests atrial fibrillation should be surgically treated when performing cardiac surgery

April 26, 2012
A recent study conducted by Northwestern Medicine® researchers published in the Journal of Thoracic and Cardiovascular Surgery, reveals that patients with an abnormal heart rhythm known as atrial fibrillation (A-fib) ...

Freeze and desist: Disabling cardiac cells that can cause arrhythmia

September 12, 2011
Many patients are responding to a new, minimally invasive way of treating irregular heartbeats by freezing out the bad cells. Atrial fibrillation (A-Fib) is one such heart rhythm disorder, and it's the most common arrhythmia ...

Loyola testing new device for treating Atrial Fibrillation

September 15, 2011
Loyola University Medical Center is testing a high-tech catheter device that's intended to improve outcomes of patients treated for atrial fibrillation, the most common irregular heartbeat.

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.